June 23rd 2023
Moderator Michael Bishop, MD leads a discussion with panelists Hannah Choe, MD, Doris M. Ponce, MD, and Bart L Scott, MD, concerning recent updates in the prevention, diagnosis, and treatment of Graft-Versus-Host Disease.
Moderator Naval G. Daver, MD leads a discussion with panelists Amir Fathi, MD, Margaret T. Kasner, MD, Eunice S. Wang, MD, providing an overview of AML pathogenesis and molecular subtypes, standard-of-care treatment approaches, and emergent therapies.
June 22nd 2023
A panel of experts review several updates in myelodysplastic syndromes (MDS) that were presented at ASCO 2023 and other recent meetings and discuss how the data may change treatment approaches in clinical practice.
June 21st 2023
Expert panelists reflect on the current state of molecular testing and management in patients with metastatic colorectal cancer, reviewing recent clinical data and considering changes in real-world practice.
June 20th 2023
Key opinion leaders review recent clinical data in the field of multiple myeloma management and consider how the treatment paradigm has evolved.
Experts discuss several recent data updates in the treatment of myeloproliferative neoplasms (MPNs) and the impact on clinical practice.
June 19th 2023
Expert panelists review recent updates in the management of relapsed/refractory diffuse large B-cell lymphoma and consider how they have impacted the real-world treatment landscape and clinical practice.
April 25th 2023
Sponsored in part by Regeneron. Content independently created by OncLive.
A panel of experts discuss updates in immunotherapy for advanced non-small cell lung cancer (NSCLC) and the impact of recent clinical trial data on treatment decision-making.
April 21st 2023
Key opinion leaders in the field of non–small cell lung cancer reflect on the evolving role of immunotherapy, alone or in combination, within various subsets of disease.
April 17th 2023
Centering discussion on clinical scenarios, expert oncologists work together to review updates in the treatment of differentiated thyroid cancer (DTC) that were presented at key conferences in 2022.
April 7th 2023
A panel of expert oncologists consider the role of HER2 expression in colorectal cancer and review novel targeted therapies in this setting.
March 20th 2023
Expert panelists reflect on the evolving treatment landscape of urothelial carcinomas and identify how it has impacted their real-world practices.
March 15th 2023
Expert panelists review updated data in the identification and management of resectable cutaneous squamous cell carcinoma and reflect on how real-world practice has evolved.
A panel of experts discuss data from recent clinical trials in renal cell carcinoma (RCC) presented at ASCO GU 2023 and other meetings, and its potential impact on clinical practice.
March 3rd 2023
Expert panelists review new data on treatment and management of nmCRPC, mHSPC, and mCRPC and consider how these data may impact clinical practice.
February 17th 2023
Expert panelists review patient case studies and discuss key updates in the treatment landscape of advanced HCC from the 2023 ASCO Gastrointestinal Cancers Symposium and beyond.
February 13th 2023
A panel of experts review the evolving treatment landscape of biliary tract cancers contextualized with their real-world experiences.
February 8th 2023
An expert panel reviews the diagnosis and treatment of metastatic colorectal cancer with a focus on the setting of HER2-positive disease.
Expert perspectives on the evolving treatment landscape of HR+ breast cancer and how novel therapies have been incorporated in practice.
February 7th 2023
Expert perspectives on molecular testing and best practices for identifying patients who may be eligible for treatment with newly approved targeted therapies.